Skip to content
EntityQ415752· pop 12· linked from 1,801 articles

Also known as LY-127809, Permax®, Pergolida, Pergolidum, Prascend

Pergolide, sold under the brand name Permax and Prascend (veterinary) among others, is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with reduced dopamine synthesis in the substantia nigra of the brain. Pergolide acts on many of the same receptors as dopamine to increase receptor activity.

Key facts

Drug.Verifiedfields
changed
Drug.verifiedrevid
464199003
Drug.image
Pergolide structure.svg
Drug.image_class
skin-invert-image
Drug.width
165px
Drug.image2
PergolideMV.png
Drug.image_class2
bg-transparent
Drug.width2
225px
Drug.tradename
Permax, Prascend (veterinary), others
Drug.pregnancy_category
B
Drug.routes_of_administration
Oral
Drug.class
Dopamine receptor agonist; Antiparkinsonian agent
Drug.ATC_prefix
N04
Drug.ATC_suffix
BC02
Drug.legal_BR
C1
Drug.legal_CA
Rx-only
Drug.legal_US_comment
Veterinary use only, withdrawn for human use
Drug.protein_bound
90%

via Wikipedia infobox

Wikidata facts

Mass
314.18167
Show 6 more facts
chemical formula
C₁₉H₂₆N₂S
isomeric SMILES
CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
canonical SMILES
CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC
World Health Organisation international non-proprietary name
pergolide
defined daily dose
3
Commons category
Pergolide
Sources (6)

via Wikidata · CC0

~6 min read

Article

10 sections
Contents
  • Medical uses
  • Pharmacology
  • Pharmacodynamics
  • Side effects
  • Addictive behaviors
  • Society and culture
  • Brand names
  • Research
  • See also
  • References

Pergolide, sold under the brand name Permax and Prascend (veterinary) among others, is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with reduced dopamine synthesis in the substantia nigra of the brain. Pergolide acts on many of the same receptors as dopamine to increase receptor activity.

It was patented in 1978 and approved for medical use in 1989. In 2007, pergolide was withdrawn from the U.S. market for human use after several published studies revealed a link between the drug and increased rates of valvular heart disease. However, a veterinary form of pergolide, marketed under the trade name Prascend, is permitted for the treatment of pituitary pars intermedia dysfunction (PPID) also known as equine Cushing's syndrome (ECS) in horses.

Connections

Categories